Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dimitrios Zardavas

Showing results (1-10 of 46) with videos related to

Pageof 5
Sort By:
Expert Opinion on Investigational Drugs|April 22, 2022
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?Dimitrios Zardavas
Annual Review of Medicine|November 12, 2014
Neoadjuvant therapy for breast cancerDimitrios Zardavas, Martine Piccart
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast CancerDimitrios Zardavas, Martine Piccart-Gebhart
Cancer Biology & Medicine|July 27, 2016
New generation of breast cancer clinical trials implementing molecular profilingDimitrios Zardavas, Martine Piccart-Gebhart
Nature Reviews. Clinical Oncology|March 6, 2013
Emerging targeted agents in metastatic breast cancerDimitrios Zardavas, José Baselga, Martine Piccart
Ecancermedicalscience|July 11, 2017
The past and future of breast cancer treatment-from the papyrus to individualised treatment approachesFelipe Ades, Konstantinos Tryfonidis, Dimitrios Zardavas
Expert Opinion on Investigational Drugs|October 14, 2017
CDK4/6 blockade in breast cancer: current experience and future perspectivesDimitrios Zardavas, Noam Pondé, Konstantinos Tryfonidis
Future Oncology (London, England)|August 2, 2013
Personalized therapy for breast cancer: a dream or a reality?Dimitrios Zardavas, Lina Pugliano, Martine Piccart
Current Opinion in Oncology|September 11, 2012
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas, Debora Fumagalli, Sherene Loi
Expert Review of Anticancer Therapy|October 22, 2013
Clinical practice-changing trials: the HERA study paradigmDimitrios Zardavas, Felipe Ades, Evandro de Azambuja
Pageof 5

Showing results (1-10 of 46) with videos related to

Sort By:
Pageof 5
Expert Opinion on Investigational Drugs|April 22, 2022
Clinical development of antibody-drug conjugates in triple negative breast cancer: can we jump higher?Dimitrios Zardavas
Annual Review of Medicine|November 12, 2014
Neoadjuvant therapy for breast cancerDimitrios Zardavas, Martine Piccart
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast CancerDimitrios Zardavas, Martine Piccart-Gebhart
Cancer Biology & Medicine|July 27, 2016
New generation of breast cancer clinical trials implementing molecular profilingDimitrios Zardavas, Martine Piccart-Gebhart
Nature Reviews. Clinical Oncology|March 6, 2013
Emerging targeted agents in metastatic breast cancerDimitrios Zardavas, José Baselga, Martine Piccart
Ecancermedicalscience|July 11, 2017
The past and future of breast cancer treatment-from the papyrus to individualised treatment approachesFelipe Ades, Konstantinos Tryfonidis, Dimitrios Zardavas
Expert Opinion on Investigational Drugs|October 14, 2017
CDK4/6 blockade in breast cancer: current experience and future perspectivesDimitrios Zardavas, Noam Pondé, Konstantinos Tryfonidis
Future Oncology (London, England)|August 2, 2013
Personalized therapy for breast cancer: a dream or a reality?Dimitrios Zardavas, Lina Pugliano, Martine Piccart
Current Opinion in Oncology|September 11, 2012
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?Dimitrios Zardavas, Debora Fumagalli, Sherene Loi
Expert Review of Anticancer Therapy|October 22, 2013
Clinical practice-changing trials: the HERA study paradigmDimitrios Zardavas, Felipe Ades, Evandro de Azambuja
Pageof 5